NPQ Plus Supplementation for Skin Health and Antioxidant Status

NCT07703215 | Completed

• 1 other identifier: IEC-2025-FMHS-0019
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties. This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.

Conditions

Eczema; Atopic Dermatitis; Skin Health; Fatigue Symptom; Sleep Quality; Antioxidant Capacity; Oxidative Stress

Keywords

NPQ Plus; Nutraceutical; Skin Health; Atopic Dermatitis; Antioxidant Status; Oxidative Stress; Fatigue; Nicotinamide Mononucleotide (NMN); Pyrroloquinoline Quinone (PQQ); Coenzyme Q10; Oligonol

Outcome Measures

Primary Outcomes (7)

• Skin Elasticity

  Skin elasticity was measured using the Cutometer® (MPA580, Courage \& Khazaka, Germany). Measurements were obtained from the left cheek, right inner forearm, and dorsal neck under standardized environmental conditions. Three consecutive readings were recorded at each site and the mean value was used for analysis. Higher values indicate greater skin elasticity.

  Baseline, Week 4, Week 8, and Week 12

• Skin Hydration

  Skin hydration was assessed using the Corneometer® CM825. Measurements were obtained from the left cheek, right inner forearm, and dorsal neck. Three readings were averaged for each anatomical site. Higher values indicate greater skin hydration.

  Baseline, Week 4, Week 8, and Week 12

• Transepidermal Water Loss (TEWL)

  Skin barrier function was evaluated by measuring transepidermal water loss using the Tewameter® TM300. Measurements were performed under standardized environmental conditions. Lower values indicate improved skin barrier integrity.

  Baseline, Week 4, Week 8, and Week 12

• Skin Inflammation

  Skin inflammation was assessed using the erythema index measured by the Mexameter® MX18. Lower erythema values indicate reduced skin inflammation.

  Baseline, Week 4, Week 8, and Week 12

• Skin Pigmentation

  Skin pigmentation was evaluated using the melanin index measured by the Mexameter® MX18. Changes in melanin index were assessed throughout the intervention.

  Baseline, Week 4, Week 8, and Week 12

• Sebum Secretion

  Sebum secretion was measured using the Sebumeter® SM815. Three measurements were obtained and averaged for each assessment site. Higher values indicate greater sebum production.

  Baseline, Week 4, Week 8, and Week 12

• Patient-Oriented Eczema Measure (POEM)

  Skin symptoms were assessed using the Patient-Oriented Eczema Measure (POEM), a validated patient-reported questionnaire evaluating eczema severity over the previous week. Lower scores indicate less severe symptoms.

  Baseline, Week 4, Week 8, and Week 12

Secondary Outcomes (6)

• Total Antioxidant Capacity (TAOC)

  Baseline, Week 4, Week 8, and Week 12

• Malondialdehyde (MDA)

  Baseline, Week 4, Week 8, and Week 12

• 3-Nitrotyrosine (3-NT)

  Baseline, Week 4, Week 8, and Week 12

• 8-Hydroxy-2'-deoxyguanosine (8-OHdG)

  Baseline, Week 4, Week 8, and Week 12

• Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

  Baseline, Week 4, Week 8, and Week 12

Study Arms (1)

NPQ Plus Supplementation

EXPERIMENTAL

Participants consumed one sachet of NPQ Plus orally once daily for 12 weeks. NPQ Plus is a multi-component nutraceutical formulation containing Oligonol®, nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Assessments were performed at baseline and at Weeks 4, 8, and 12 to evaluate skin health, antioxidant status, fatigue, and self-perceived well-being.

Dietary Supplement: NPQ Plus

Interventions

NPQ Plus DIETARY_SUPPLEMENT

NPQ Plus is a dietary supplement containing Oligonol® (polyphenols), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Participants consumed one sachet orally once daily for 12 weeks.

NPQ Plus Supplementation

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months.
• Willing and able to consume one sachet of NPQ Plus daily for 12 weeks.
• Willing to attend all scheduled study visits and assessments.
• Able to understand the study procedures and provide written informed consent.

You may not qualify if:

• Consumption of dietary supplements intended to improve skin health within the previous 3 months.
• Pregnant or breastfeeding women.
• Known allergy or hypersensitivity to any ingredient in NPQ Plus.
• Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments.
• Participation in another clinical study within the previous 3 months.
• Unable or unwilling to comply with the study protocol.

Sponsors & Collaborators

• N REMEDIER (M) SDN BHD: lead
• UCSI University: collaborator
• JScience Consultancy PLT: collaborator

Study Sites (1)

UCSI University

Cheras, Kuala Lumpur, 56000, Malaysia

Location

Related Publications (2)

• Hu T, Wang F, Duan Q, Zhao X, Yang F. Prevalence of fatigue and perceived fatigability in older adults: a systematic review and meta-analysis. Sci Rep. 2025 Feb 9;15(1):4818. doi: 10.1038/s41598-025-88961-x.

  PMID: 39924533 BACKGROUND

• Leo TK, Tan ESS, Amini F, Rehman N, Ng ESC, Tan CK. Effect of Rice (Oryza sativa L.) Ceramides Supplementation on Improving Skin Barrier Functions and Depigmentation: An Open-Label Prospective Study. Nutrients. 2022 Jun 30;14(13):2737. doi: 10.3390/nu14132737.

  PMID: 35807914 BACKGROUND

MeSH Terms

Conditions

Eczema; Dermatitis, Atopic; Fatigue; Sleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Study Officials

• Chung Keat Tan, PhD

  UCSI University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This was a single-arm, open-label, prospective interventional study evaluating the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being. Participants consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were conducted at baseline and at Weeks 4, 8, and 12 to evaluate changes in skin biophysical parameters, antioxidant biomarkers, fatigue, and participant-reported outcomes.

Study Record Dates

• First Submitted: July 8, 2026
• First Posted: July 14, 2026
• Study Start: January 1, 2026
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: July 14, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Beginning 6 months after publication of the study results and ending 5 years after publication.
• Access Criteria: Qualified researchers may request access to de-identified individual participant data by submitting a written request to the Principal Investigator. Requests must include a research proposal outlining the intended use of the data. Access will be granted following review and approval by the Principal Investigator and the sponsoring institution, subject to applicable ethical and institutional data-sharing requirements.

Locations

MY (1)